Tag Archives: Novartis AG

Novartis 1Q results remain insomnia cure; investors plead for something, anything to get excited about

The News: Novartis AG shares moved higher Tuesday (April 25, 2017) after the pharmaceuticals group clung to full-year earnings targets and barely beat analysts’ estimates for first-quarter earnings. The Swiss… Read more »

Novartis teams up with Allergan in NASH gamble; heated race to riches in full swing

The News: Allergan PLC (Dublin IRL) is expanding its research and development program on non-alcoholic steatohepatitis (NASH) through a collaboration with Novartis AG (Basel CHE) that will test a new… Read more »

China’s FDA approves AstraZeneca’s lung-cancer drug in new “fast-track” program; European drugmakers beating US to world’s biggest drug market

The News: AstraZeneca PLC (London) has won approval for its lung-cancer pill Tagrisso in China, a key market for the potential blockbuster medicine. Tagrisso is designed to help cancer patients… Read more »

Indy’s Eli Lilly making noise with cancer push; Brickyard neighbor revving its drug-discovery engine

I’ve been to the headquarters of Eli Lilly & Co.–about 15 minutes (or about 5 miles) from the “Brickyard” where the Indianapolis 500 is run each year. The racing is… Read more »

Icahn’s latest target, Bristol-Myers, may play hard-to-get; unless Pfizer comes a courting

The News: Activist investor Carl Icahn just announced his latest target: Bristol-Myers Squibb Co., reports the Wall Street Journal. Bristol-Myers has been the focus of several activist investors in recent… Read more »

Trump and pharma execs make nice; what, Sen. Sanders too?

The News: Last week (January 30, 2017), President Trump promised some of the nation’s top drug-company executives in a meeting at the White House that he would shrink Food and… Read more »

Novartis repeats possible spinoff for Alcon eyecare unit; the best laid plans gone awry?

The News: Novartis AG (Basel CHE), which spent several years and more than $50 billion acquiring the Alcon eye-care company, signaled it’s ready to give up on most of the… Read more »

Mallinckrodt will pay $100 million to settle drug antitrust (price-gouging) charges; why competition, not fines, is the only antidote

The News: Irish drugmaker Mallinckrodt PLC (Dublin) and a US subsidiary will pay $100 million and agree to other conditions to settle government antitrust allegations they unlawfully prevented competition for… Read more »

Drugs that may shape 2017 and the trends molding new-drug discovery

Here’s a look at the drugs that may shape 2017, compliments of FirstWord Pharma. It’s a list of some of the products I agree are likely to dominate industry news… Read more »

Gilead starts 2017 by snatching Novartis cancer specialist; a harbinger of early (and ferocious) M&A?

Gilead Sciences Inc. (Foster City CA) has poached a top cancer specialist from Swiss drugmaker Novartis AG (Basel) as the US healthcare group sharpens its focus on oncology. Alessandro Riva… Read more »